Overview

Study of rESP Injection for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis

Status:
Recruiting
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
A phase 2, randomized, open label, active comparator parallel controlled study to explore the dosage regiment of rESP, and evaluate its efficacy, safety and pharmacokinetic characteristics in the treatment of anemia in chronic renal failure patients with hemodialysis
Phase:
Phase 2
Details
Lead Sponsor:
Shenyang Sunshine Pharmaceutical Co., LTD.